Verkazia FDA Approval History
Last updated by Judith Stewart, BPharm on July 13, 2021.
FDA Approved: Yes (First approved June 23, 2021)
Brand name: Verkazia
Generic name: cyclosporine
Dosage form: Ophthalmic Emulsion
Company: Santen Inc.
Treatment for: Vernal Keratoconjunctivitis
Verkazia (cyclosporine) is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.
- Verkazia works by inhibiting T-cell activation and reducing the level of immune cells and mediators that cause the chronic, severe, and potentially debilitating allergic inflammation of the ocular surface associated with vernal keratoconjunctivitis.
- Verkazia is administered by instilling one drop in each affected eye four times daily.
- Common adverse reactions include eye pain and eye pruritus.
Development timeline for Verkazia
| Date | Article |
|---|---|
| Jun 24, 2021 | Approval FDA Approves Verkazia (cyclosporine ophthalmic emulsion) for the Treatment of Vernal Keratoconjunctivitis |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
